European Journal of Cancer
Volume 37, Issue 4 , Pages 503-511 , March 2001

Effects of hexadecylphosphocholine on thrombocytopoiesis

Received 11 April 2000 ,Revised 31 August 2000 ,Accepted 5 September 2000.

References 

  1. Andreesen R, Modolell M, Weltzien HU, et al.  Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res. 1978;38:3894–3899
  2. Andreesen R, Modolell M, Munder PG. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood. 1979;54:519–523
  3. Berdel WE, Bausert WR, Weltzien HU, Modolell M, Wickman KH, Munder PG. The influence of alkyl-phospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3 Lewis Lung carcinomas. Eur. J. Cancer. 1980;16A:1199–1204
  4. Berdel WE, Schlehe H, Fink U, et al.  Early tumor and leukemia response to alkyl-lysophospholipids in a phase I study. Cancer. 1982;50:2011–2015
  5. Berdel WE, Greiner E, Fink U, et al.  Cytotoxicity of alkyl-lysophospholipids derivatives and low alkyl-cleavage enzyme activities in rat brain tumor cells. Cancer Res. 1983;43:541–545
  6. Unger C, Eibl H, Breiser A, et al.  Hexadecylphosphocholine (D18506) in the topical treatment of skin metastases (a phase I trial). Onkologie. 1988;11:295–296
  7. Unger C, Peukert M, Sindermann H, Hilgard P, Nagel GA, Eibl H. Hexadecylphosphocholine in the treatment of skin metastasis in breast cancer patients. Cancer Treatment Rev. 1990;17:243–246
  8. Becher R, Kloke O, Füger A, et al.  Phase II trial of orally administered miltefosine in advanced colorectal cancer. Onkologie. 1993;16:11–15
  9. Planting A, Verweji J, Hoff A, Drees A, Seynalve C, Stoter G. Phase II study of daily oral hexadecylphosphocholine in advanced colorectal cancer. Ann. Oncol. 1990;1(Suppl.):46
  10. Berdel WE, Becher R, Edler L, et al.  Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non small cell lung cancer. A phase II study. Onkologie. 1992;15:238–242
  11. Dummer R, Röger J, Vogt T, et al.  Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. In:  Eibl H,  Hilgard P,  Unger C editor. Progress in Experimental Tumor Research, vol. 24. Alkylphosphocholines: New Drugs in Cancer Therapy. Basel: Karger Verlag; 1992;p. 160–170
  12. Diomede L, Piovani B, Re F, Principe P, Colotta F, Modest E, et al. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in leukemic cells. Int. J. Cancer. 1994;57:645–649
  13. Honma Y, Kasukabe T, Hozumi M, Tsushima S, Nomura H. Induction of differentiation of cultured mouse myeloid leukemia cells by alkyllysophospholipids. Cancer Res. 1981;41:3211–3216
  14. Hochhuth C, Berkovic D, Eibl H, Unger C, Doenecke D. Effects of neoplastic phospholipids on parameters of cell differentiation in U937 cells. J. Cancer Res. Clin. Oncol. 1990;116:459–466
  15. Schallier DC, Bruyneel EA, Storme GA, Hilgard P, Mareel MM. Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res. 1991;11:1285–1292
  16. Vehmeyer K, Scheurich P, Eibl H, Unger C. Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2. Cellular Immunol. 1991;137:232–238
  17. Hochhuth C, Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF m RNA in human mononuclear cells. Cellular Immunol. 1992;141:161–168
  18. Modolell M, Andreesen R, Pahlke W, Brugger U, Munder PG. Disturbance of phospholipid metabolism during selective destruction of tumor cells induced by alkylphospholipids. Cancer Res. 1985;39:4681–4686
  19. Shoji M, Raynor RL, Fleer EAM, Eibl H, Vogler WR, Kuo JF. Effects of hexa-decylphosphocholine on protein kinase C and TPA-induced differentiation of HL 60 cells. Lipids. 1988;26:145–149
  20. Zheng B, Oishi K, Shoji M, et al.  Inhibition of protein kinase C (sodium plus potassium) activated adenosine triphosphatase and sodium pump by synthetic phospholipid analogues. Cancer Res. 1990;50:3025–3031
  21. Powis G, Seewald MJ, Gratas C, Milder DC, Riebow J, Modest EJ. Selective inhibitation of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 1992;52:2835–2840
  22. Berkovic D, Goeckenjan M, Lüders S, Hiddemann W, Fleer EAM. Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine specific phospholipase C in human leukemia cells. J. Exp. Ther. Oncol. 1996;1:302–311
  23. Berkovic D, Lüders S, Goeckenjan M, Hiddemann W, Fleer EAM. Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Biochem. Pharmacol. 1997;53:1725–1733
  24. Ruiter GA, Zerp SF, Bartelink H, van-Blitterwijk WJ, Verheji M. Alkyllysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 1999;59:2457–2463
  25. Pronk LC, Planting AST, Oosterom R, Drogendijk TE, Stoter G, Verweji J. Increases in leucocyte and patelet counts induced by the alkyl-phospholipid hexadecylphosphocholine. Eur. J. Cancer. 1994;30A:1019–1022
  26. Vehmeyer K, Kim DJ, Nagel GA, Eibl H, Unger C. Effects of ether lipids on mouse granulocyte macrophage progenitor cells. Cancer Chemother. Pharmacol. 1989;24:58–60
  27. Shames R, Ruis NM, Valone FH. Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine (ET-18-OCH3). Int. J. Immunopharmacol. 1994;16:335–343
  28. Andreesen R, Osterholz J, Luckenbach GA, et al.  Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J. Natl. Cancer Inst. 1984;72:53–59
  29. Kosano H, Takatani O. Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. Cancer Res. 1988;49:2868–2870
  30. Shoji M, Fukuhara T, Winton EF, Berdel WE, Vogler WR. Different mechanisms of inhibitation by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony stimulating factor binding to human leukemic cell lines. Exp. Hematol. 1994;22:13–18
  31. Travers JB, Li Q, Kniss DA, Fertel RH. Identification of functional platelet-activating factor receptors in Raji lymphoblasts. J. Immunol. 1989;143:3708–3713
  32. Fleer EAM, Berkovic D, Eibl H, Unger C. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids. 1993;28:731–736
  33. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine (oral treatment of visceral leishmaniasis in mice). Antimicrob. Agents Chemother. 1992;352:1630–1634
  34. Jha TK, Sundar S, Thakur CP, et al.  Miltefosine, an oral agent, for the treatment of indian visceral leishmaniasis. N. Engl. J. Med. 1999;341:1795–1800
  35. Murray HW, Delph-Etienne S. Visceral leishmaniasis activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 2000;181/2:779–795

PII: S0959-8049(00)00394-4

European Journal of Cancer
Volume 37, Issue 4 , Pages 503-511 , March 2001

Article Tools

* Image Usage & Resolution